CN101664533B - Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method - Google Patents
Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method Download PDFInfo
- Publication number
- CN101664533B CN101664533B CN 200810051138 CN200810051138A CN101664533B CN 101664533 B CN101664533 B CN 101664533B CN 200810051138 CN200810051138 CN 200810051138 CN 200810051138 A CN200810051138 A CN 200810051138A CN 101664533 B CN101664533 B CN 101664533B
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- radix
- chinese
- chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 206010020718 hyperplasia Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000001684 chronic effect Effects 0.000 title claims abstract description 12
- 230000001154 acute effect Effects 0.000 title claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 5
- 238000005453 pelletization Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 3
- 239000000314 lubricant Substances 0.000 claims abstract description 3
- 239000008107 starch Substances 0.000 claims abstract description 3
- 235000019698 starch Nutrition 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 15
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 241000407170 Curcuma Species 0.000 claims description 5
- 235000014375 Curcuma Nutrition 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000012567 medical material Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000000284 extract Substances 0.000 abstract description 6
- 230000002124 endocrine Effects 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 229940011871 estrogen Drugs 0.000 abstract description 2
- 239000000262 estrogen Substances 0.000 abstract description 2
- 241000675108 Citrus tangerina Species 0.000 abstract 3
- 241000213006 Angelica dahurica Species 0.000 abstract 2
- 244000163122 Curcuma domestica Species 0.000 abstract 2
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 2
- 244000150195 Cyperus longus Species 0.000 abstract 2
- 235000018109 Cyperus longus Nutrition 0.000 abstract 2
- 244000075634 Cyperus rotundus Species 0.000 abstract 2
- 241000935235 Fritillaria meleagris Species 0.000 abstract 2
- 235000005010 Scirpus paludosus Nutrition 0.000 abstract 2
- 240000001949 Taraxacum officinale Species 0.000 abstract 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 2
- 235000008326 Trichosanthes anguina Nutrition 0.000 abstract 2
- 244000078912 Trichosanthes cucumerina Species 0.000 abstract 2
- 235000003373 curcuma longa Nutrition 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 235000013976 turmeric Nutrition 0.000 abstract 2
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 230000036592 analgesia Effects 0.000 abstract 1
- 239000000469 ethanolic extract Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 description 29
- 241000700159 Rattus Species 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 210000005075 mammary gland Anatomy 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 7
- 240000001624 Espostoa lanata Species 0.000 description 6
- 235000009161 Espostoa lanata Nutrition 0.000 description 6
- 206010020880 Hypertrophy Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002445 nipple Anatomy 0.000 description 6
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 208000030270 breast disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000008508 epithelial proliferation Effects 0.000 description 3
- 229950002007 estradiol benzoate Drugs 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000008840 bushen tiaochong Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000854 inhibitional effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a Chinese medicament for treating acute and chronic mammary hyperplasia and a preparation method. The Chinese medicament consists of the following raw materials in portion by weight: 4 to 20 portions of dandelion, 2 to 10 portions of Chinese thorowax root, 2 to 10 portions of sauted green tangerine peel, 2 to 10 portions of fritillary bulb, 2 to 10 portions of turmeric root-tuber, 3 to 15 portions of snakegourd fruit, 2 to 10 portions of Chinese angelica, and 2 to 10 portions of sauted nutgrass galingale rhizome. The preparation method comprises the following steps: extracting the fritillary bulb and the Chinese angelica by using ethanol, and concentrating the ethanol extract to form an extract; extracting the dandelion, a part of green tangerine peel, the snakegourd fruit, the turmeric root-tuber and the nutgrass galingale rhizome by using water, and concentrating the water extract to form an extract; and mixing the two extracts, then evenly mixing the mixed extract and a part of green tangerine peel which is ground into fine powder, reducing the pressure and drying the mixture, crushing the mixture and adding proper amount of accessories into the mixture, evenly mixing and pelletizing the mixture, adding proper amount of dried starch and lubricant into the mixture, and evenly mixing the mixture to obtain the Chinese medicament. The Chinese medicament used for treating acute and chronic mammary hyperplasia diseases has obvious inhibition or treatment effect on the mammary hyperplasia caused by estrogen reduction and endocrine dyscrasia, and has obvious analgesia and anti-inflammatory effects at the same time.
Description
Technical field
The invention belongs to the new Chinese medicine technical field, be specifically related to a kind of Chinese medicine preparation for the treatment of the acute and chronic mammary hyperplasia disease and preparation method thereof.
Technical background
Cyclomastopathy belongs to the category of the traditional Chinese medical science " nodules of the breast ".Be young women commonly encountered diseases, frequently-occurring disease, account for more than 70% of mastopathy.Primary disease is comparatively common, and its sickness rate of domestic report and is mainly in 30～50 years old women about 10%, and the man also has generation.Modern medicine thinks that it is relevant with endocrine dysfunction, take mastalgia and lump in breast as principal character.Chinese medicine thinks that the etiology and pathogenesis of primary disease is depression of liver-QI, the expectorant blood coagulation stasis of blood, Chong and Ren channel disorder; Wherein Chong and Ren channel disorder is for falling ill originally, and depression of liver-QI, the expectorant blood coagulation stasis of blood are the mark of morbidity, and disease located in liver spleen kidney, characteristic of disease are deficiency in origin and excess in superficiality.Zhang Xiantao, Guo Sihong, Su Ying think that stagnation of QI due to depression of the liver is the main cause that nodules of the breast occurs, Xu Lvhe according to diseases such as primary disease distending pain of the breast caking, dim gas uncomfortable in chest in being in a very depressed state, increasing the weight of during menstrual onset, think that the primary disease pathogenesis is liver, liver is appointed with punching and influences each other depression of liver-QI, Chong and Ren channel disorder, through water delegation, irritability must be relaxed, Gu all diseases all subtract, therefore on the method for the treatment of take dispersing the stagnated live-QI to relieve the stagnation of QI as main.Contemporary well-known doctor Gu Baihua basis for many years clinical experience proposes Chong and Ren channel disorder and the common viewpoint of causing a disease of stagnation of QI due to depression of the liver, is extensively approved clearly proposition on treating " control addiction elder generation treating the liver, the controlled atmosphere addiction is certainly clear ".Ni Dajun also obtains good effect with transferring liver ruling by law to treat the Chong and Ren channel disorder type mastoproliferation disease, proved the reasonability of controlling cyclomastopathy from the liver opinion, Gong Yunbin also thinks that the generation of nodules of the breast and stagnation of QI due to depression of the liver are in close relations, because the stagnation of QI can cause blood stasis expectorant solidifying, and the two can become paathogenic factor, and the stagnation of QI is increased the weight of.Lin Yi, Xu Guisheng think that then Chong and Ren channel disorder is the basic of nodules of the breast morbidity, and the methods that adopt Bushen Tiaochong to appoint have obtained satisfactory effect clinically in the treatment.
Show have every year the hundreds of thousands women to be forced to carry out excision because suffering from this disease according to hygiene department's statistics.Mastopathy is not distinguished by lump, if optimum, adopt orally taken for curing, can eliminate at short notice fully; If pernicious, even if the caking of grain of rice size is wanted untimely treatment, also can bring out canceration, the women got cyclomastopathy, mammary gland fibroma thus, and the mastopathy such as lump in breast must in time check treatment.
Although at present clinical the chemotherapy hyperplasia of mammary glands is arranged, certain therapeutical effect is also arranged, toxic and side effects is relatively large.Although some compound Chinese medicinal preparation treatment hyperplasia of mammary glands are also arranged, and curative effect is not bery desirable.For example RUKANG PIAN is aided with the 17 flavor Chinese medicines such as Concha Ostreae, Spica Prunellae, Radix Salviae Miltiorrhizae, Radix Scrophulariae, Bulbus Fritillariae Thunbergii and forms take the Radix Astragali as monarch drug.Its production technology is that 4 kinds of compositions are pulverized, and all the other 13 kinds of flavour of a drug decoct with water secondary, and decocting liquid precipitates with ethanol, removes macromolecular substances (polysaccharide etc.); Modern pharmacology studies show that, the polysaccharide component in the Radix Astragali, the Bulbus Fritillariae Thunbergii has higher physiologically active, do not reach the purposes that effective ingredient is all kept.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine for the treatment of acute and chronic mammary hyperplasia, the cyclomastopathy that estrogen decrease and endocrine disturbance are caused all has obvious inhibition or therapeutical effect, has simultaneously obvious antiinflammatory, analgesic activity.
Another object of the present invention is to provide a kind of preparation method for the treatment of the Chinese medicine preparation of acute and chronic mammary hyperplasia disease.
The present invention is comprised of the Chinese crude drug of following parts by weight ratio: 4～20 parts of Herba Taraxacis, 2～10 parts of Radix Bupleuri, 2～10 parts of parch skins, 2～10 parts of Bulbus Fritillariae Thunbergiis, 2～10 parts of Radix Curcumaes, 3～15 parts of Fructus Trichosanthis, 2～10 parts of Radix Angelicae Sinensis, 2～10 parts of stir-fry Rhizoma Cyperis.
Best medical material ratio of weight and number of the present invention is: 12 parts of Herba Taraxacis, 6 parts of Radix Bupleuri, 6 parts of parch skins, 6 parts of Bulbus Fritillariae Thunbergiis, 6 parts of Radix Curcumaes, 9 parts of Fructus Trichosanthis, 6 parts of Radix Angelicae Sinensis, 6 parts of stir-fry Rhizoma Cyperis.
The preparation method of Chinese medicine of the present invention is comprised of following steps: a, get the raw materials ready: take by weighing raw materials of traditional Chinese medicinal materials according to above-mentioned consumption, each Chinese crude drug cleaned dry, described share is for subsequent use by choosing, with Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, pulverize about half of Pericarpium Citri Reticulatae Viride, cross 100 mesh sieves for subsequent use; B, ethanol extraction: the Radix Bupleuri of described weight quota, Bulbus Fritillariae Thunbergii, Radix Angelicae Sinensis are added the alcohol reflux twice of 6-12 times of weight, concentration 40-90%, then filter, the extractum of relative density 1.10-1.40 with filtrate recycling ethanol and when being concentrated into 60 degrees centigrade; C, water extraction: half Pericarpium Citri Reticulatae Viride, Herba Taraxaci, Radix Curcumae, Fructus Trichosanthis, Rhizoma Cyperi that pulverizing is remaining, decoct with water three times, each amount of water is 6-12 times, decocts 1-4 hour at every turn, then filter the extractum of relative density 1.10-1.40 when filtrate is concentrated into 60 degrees centigrade; D, combination drying: with two kinds of extractum of gained and Pericarpium Citri Reticulatae Viride fine powder mixing among step b and the step c, in 50-80 degree centigrade of drying under reduced pressure, add the appropriate amount of auxiliary materials mixed pelletization after pulverizing, drying adds appropriate amount of auxiliary materials and lubricant.
The dosage form of the pharmaceutical composition finished product preparation for the treatment of dysmenorrhea disease of the present invention is acceptable any dosage form of routine techniques method preparation on the pharmaceutics, such as granule, pill, capsule, soft capsule, tablet, mixture, oral liquid etc.
Medicine of the present invention is oral medicine, and consumption is a 10-14 gram, 3 times on the one.
Technical scheme of the present invention is based on motherland's medical science to understanding and the Therapeutic Principle of acute and chronic mammary hyperplasia disease pathogenesis, with reference to modern pharmacological research achievement, according to depressed liver-energy dispersing and QI regulating, logically transfers punching to appoint, blood circulation promoting and blood stasis dispelling, and the disappear principles of formulating prescriptions of addiction of eliminating stagnation form.Be monarch drug by adopting Herba Taraxaci, Radix Bupleuri, tool Shugan Qingre, the disappear effect of addiction of eliminating stagnation; Fructus Trichosanthis, Bulbus Fritillariae Thunbergii, Pericarpium Citri Reticulatae Viride, Radix Curcumae are ministerial drug, and Herba Taraxaci, Radix Bupleuri get Fructus Trichosanthis, Bulbus Fritillariae Thunbergii is auxiliary then removing heat-phlegm, the disappear Li Youhong of addiction of eliminating stagnation; Pericarpium Citri Reticulatae Viride, Radix Curcumae are aided then dispersing the stagnated live-QI to relieve the stagnation of QI, the merit benefit of the blood stasis dispelling of circulation of qi promoting is clear; Radix Angelicae Sinensis, Rhizoma Cyperi one blood of supervising the cooking, a main circulation of qi promoting, the two blood of regulating the flow of vital energy is transferred punching to appoint and is adjuvant.The all medicines in full side are pulled together, and long memorial liver and qi altogether logically transfers punching to appoint, blood circulation promoting and blood stasis dispelling, the disappear merit of addiction of eliminating stagnation.The present invention is on preparation technology, and the part Pericarpium Citri Reticulatae Viride is ground into fine powder, and remainder adopts different extracting method according to the not same-action of various flavour of a drug, and preparation technology's maximum possible extracts the effective ingredient of each flavour of a drug.
Show through pharmacodynamic study, gastric infusion can significantly reduce E continuously
2, P, LH content, significantly reduce the rat height of nipples and reduce the uterus coefficient, significantly reduce plasma viscosity, though whole blood viscosity and packed cell volume are had reduction trend, not statistically significant.Pathological examination shows, the Pu Chai addiction sheet that disappears can obviously reduce acinus and forms, and suppresses acinus epithelial proliferation, acinus expansion and secretions hypertrophy, and cyclomastopathy is had preferably inhibitory action; The swollen granulation tissue hyperplasia of rat cotton balls there is obvious inhibitory action; The Pu Chai mice ear that addiction sheet 1,0.5g/kg group xylol causes that disappears has obvious inhibitory action; The Pu Chai mouse writhing reaction that addiction sheet 1g, 0.5g/kg Dichlorodiphenyl Acetate cause that disappears has obvious inhibitory action.
Show through toxicologic study: Wistar rat oral gavage, 26 weeks of successive administration (gavage), 2 weeks of Reversible observe.General state through observing rat administration treated animal after reaching drug withdrawal during the administration, growth promoter, diet, drinking-water, defecation etc. are showed no unusual, the more equal no significant difference of the weight of animals and organ index and matched group, every detection index: routine blood test (erythrocyte, leukocyte, hemoglobin, platelet, Leukocyte classification); Thrombinogen; Blood biochemical is learned and is checked (aspartic acid aminotransferase, ALT, alkali phosphatase, total protein, albumin, blood urea nitrogen, T-CHOL, blood glucose, creatinine, total bilirubin) and the more equal no significant difference of matched group, checks under the main organs specimen mirror of pathological observation and censorship rat to be showed no the pathological change relevant with drug toxicity.Show that the Pu Chai addiction sheet toxicity that disappears is lower, the clinical dosage oral administration safety is larger.
Prove determined curative effect of the present invention through zoopery; Long term toxicity test proves, the present invention takes (3～6 months) and substantially has no side effect in therapeutic process.Adopt regulating thoroughfare and controlling vessel ruling by law to treat cyclomastopathy, not only can correct hormone disturbance, also can suppress the generation of breast carcinoma.
The specific embodiment
Embodiment 1
1, Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Bulbus Fritillariae Thunbergii, Radix Curcumae, Fructus Trichosanthis, Radix Angelicae Sinensis and Rhizoma Cyperi are cleaned dried, get Herba Taraxaci 400 grams, Radix Bupleuri 200 grams, Pericarpium Citri Reticulatae Viride 200 grams, Bulbus Fritillariae Thunbergii 200 grams, Radix Curcumae 200 grams, Fructus Trichosanthis 300 grams, Radix Angelicae Sinensis 200 grams, Rhizoma Cyperi 200 grams, Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, the 110g Pericarpium Citri Reticulatae Viride is pulverized, crossed 100 mesh sieves for subsequent use;
2, ethanol extraction: Radix Bupleuri, Bulbus Fritillariae Thunbergii, Radix Angelicae Sinensis are added the alcohol reflux twice that 6-12 doubly measures 40-90%, then filter, the extractum of relative density 1.10-1.40 with filtrate recycling ethanol and when being concentrated into 60 degrees centigrade;
3, water extraction: Pericarpium Citri Reticulatae Viride, Herba Taraxaci, Fructus Trichosanthis, Radix Curcumae and Rhizoma Cyperi that pulverizing is remaining, decoct with water three times, each amount of water is 6-12 times, decocts 1-4 hour at every turn, then filters the extractum of relative density 1.10-1.40 when filtrate is concentrated into 60 degrees centigrade;
4, combination drying: with two kinds of extractum of gained in step 2 and the step 3 and Pericarpium Citri Reticulatae Viride fine powder mixing, in 50-80 degree centigrade of drying under reduced pressure, add the appropriate amount of auxiliary materials mixed pelletization after pulverizing.
Can make tablet, capsule or electuary as required, during the preparation Tablet and Capsula, the adjuvant of adding is generally starch, dextrin or magnesium stearate.During the preparation electuary, the adjuvant of adding is generally sugar or other sweeting agents.
Embodiment 2
Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Bulbus Fritillariae Thunbergii, Radix Curcumae, Fructus Trichosanthis, Radix Angelicae Sinensis and Rhizoma Cyperi cleaned dry, get Herba Taraxaci 2000 grams, Radix Bupleuri 1000 grams, Pericarpium Citri Reticulatae Viride 1000 grams, Bulbus Fritillariae Thunbergii 1000 grams, Radix Curcumae 1000 grams, Fructus Trichosanthis 1500 grams, Radix Angelicae Sinensis 1000 grams, Rhizoma Cyperi 1000 grams, Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, Pericarpium Citri Reticulatae Viride 550g is pulverized, cross 100 mesh sieves for subsequent use.Other step is with embodiment 1.
Embodiment 3
Herba Taraxaci, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Bulbus Fritillariae Thunbergii, Radix Curcumae, Fructus Trichosanthis, Radix Angelicae Sinensis and Rhizoma Cyperi cleaned dry.Get 1200 parts of Herba Taraxacis, 600 parts of Radix Bupleuri, 600 parts on Pericarpium Citri Reticulatae Viride, 600 parts of Bulbus Fritillariae Thunbergiis, 600 parts of Radix Curcumaes, 900 parts of Fructus Trichosanthis, Radix Angelicae Sinensis 600 grams and Rhizoma Cyperi 600 grams, Pericarpium Citri Reticulatae Viride 310g is pulverized in Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, crosses 100 mesh sieves for subsequent use; Other step is with embodiment 1.
Effect experiment
The medicine that the present invention makes, through zoopery, the cyclomastopathy rat had significant therapeutical effect, reduce estradiol, progesterone and lutropin content, rat hypertrophy uterus significantly dwindles, the pathological examination prompting can obviously reduce acinus and form, and suppresses acinus epithelial proliferation, acinus expansion and secretions hypertrophy, improves the Epithelial hyperplasia degree; The mice internal organs pain that Dichlorodiphenyl Acetate causes has significant inhibitory action; The rat proliferative inflammation that cotton balls is caused has significant inhibitory action; The chmice acute inflammation that xylol causes also has significant inhibitory action; Can reduce under the pathological state plasma viscosity in the hemorheology of rat.
In zoopery, the medicine that the present invention makes is tablet, the called after Pu bavin addiction sheet that disappears, and contrasting tested medicine is RUKANG PIAN, specifically tests as follows:
Tested medicine: the Pu Chai addiction sheet that disappears is Film coated tablets, removes aobvious sepia behind the film-coat, and every gram contains crude drug 3.42 grams, and Science and Technology Ltd. provides by the Jilin great achievement, lot number: 070504; RUKANG PIAN, safe and sound Taisho Pharmaceutical company limited factory produces, lot number: 20060520.The equal gastric infusion of said medicine, matched group give same volume (20ml/kg) water.
Reagent: estradiol benzoate injection, Shanghai General Pharmaceutical Co., ltd., lot number: 050105; Progesterone injection, Zhejiang Province XianJu Pharmacy stock Co., Ltd, lot number: 070502; Dimethylbenzene, organic synthesis chemical plant, Wuhan, lot number: 891009.
Instrument: YDA-IV type blood viscometer, Beijing Hong Run reach the production of development in science and technology company limited.
Animal: Kunming mouse 20 ± 2g, be female, available from Changchun Biological Products Institute, the quality certification number: SCXK-2002-0001; Wistar rat 150～240g is female, and preclinical medicine institute of Jilin University zoopery center provides, quality certification SCXK-(Ji) 2003-0001.
Each experiment body weight difference mice is no more than 4g, and rat is no more than 30g.
Method and result
One, on the impact of hyperplasia of mammary gland model rat
Get 60 of healthy adult unpregnancy female rats, divide equally at random six groups, be respectively matched group, model group, positive control RUKANG PIAN group (0.28g/kg) and Pu bavin disappear addiction sheet group (0.7,0.35,0.175g/kg).Except matched group, all the other each groups after 25 days, change intramuscular injection every day Progesterone 0.5mg/kg into, continuous 5 days by 0.5mg/kg intramuscular injection every day estradiol benzoate.Simultaneously respectively organize gavage and give tested medicine, 4 weeks of successive administration.After the last administration 24 hours, with the anesthesia of 20% urethane, abdominal aortic blood 5ml, after the 2ml natural subsidence, centrifugal (3000r/min) 5min gets upper serum and is used for measuring hormone-content, the sodium citrate anticoagulant of 3ml blood, be used for measuring hemorheology index, then rat is put to death in the cervical vertebra dislocation, with second pair of height of nipples of vernier caliper measurement, draw materials through basad maximum tangent plane of nipple again, conventional fixing, paraffin embedding, section, HE dyeing are observed histopathology and are changed under the light microscopic.Separating uterus is rejected fatty tissue on every side again, weighs rapidly.The results are shown in Table 1, table 2, table 3.
The impact of addiction sheet on hyperplasia of mammary gland model rat uterus coefficient and height of nipples that disappear of table 1. Pu bavin
Compare * P＜0.05, * * P＜0.01.x ± S. with model group
The impact of addiction sheet on hyperplasia of mammary gland model rat hormonal readiness that disappear of table 2. Pu bavin
Compare * P＜0.05, * * P＜0.01.x ± S. with model group
The impact of addiction sheet on hemorheology of rat that disappear of table 3. Pu bavin
Compare * P＜0.05, * * P＜0.01 with model group
The result shows, rat muscle injection estradiol benzoate and Progesterone cause rat mammary gland hypertrophy, E
2, P, LH content compared with normal matched group obviously raise, perusal as seen, the rat nipple is red and swollen or increase, and shows that the rat mammary gland model of hyperplasia sets up; Disappear addiction sheet 0.7,0.35g/kg group and RUKANG PIAN 0.28g/kg group of Pu Chai all can significantly reduce E
2, P, LH content; Significantly reduce the rat height of nipples and reduce the uterus coefficient; Pu Chai addiction sheet 0.7, the 0.35g/kg group that disappears significantly reduces plasma viscosity, though whole blood viscosity and packed cell volume are had reduction trend, not statistically significant.
Pathological examination shows, the mammary gland of control rats all finds no the cyclomastopathy symptom, the obvious hypertrophy of the lobules of mammary gland of model group rat, conduit cavity and acinus expansion are obviously, acinus increases, and lumen of gland and ductal ectasia also have secretions, and disappear addiction sheet high dose group and RUKANG PIAN group of Pu Chai can obviously reduce acinus and form, suppress acinus epithelial proliferation, acinus expansion and secretions hypertrophy, to cyclomastopathy in, low dose group is more effective.
Two, on the swollen impact of rat granuloma
Get 50 of rats, be divided at random five groups, be respectively matched group, positive control RUKANG PIAN group (0.28g/kg) and the Pu bavin addiction sheet group (0.7,0.35,0.175g/kg) that disappears.The etherization rat, cut off respectively the 1cm osculum after the bilateral axillary regions sterilization, bilateral is respectively implanted 50mg sterilization cotton balls (autoclaving, each adds ampicillin 10mg/ml, 50 ℃ of oven for drying), each organizes front 3 days of rat Rhizoma Atractylodis Macrocephalae to postoperative administration every day in 7 day 1 time, amount to 10 times, 1 hour (postoperative 7 days) sacrificed by decapitation rat is cut former otch after the last administration, and cotton balls and hyperplastic tissue are together taken out, 70 ℃ of dryings, accurately weigh, claim to such an extent that weight deducts cotton balls weight and is the granulation tissue hyperplasia degree, the results are shown in Table 2.
The impact of addiction sheet on the rat chronic granulation tissue hyperplasia that disappear of table 4. Pu bavin
With matched group relatively: * * P＜0.01*P＜0.05.x ± S.
The result shows, disappear addiction sheet 0.7,0.35,0.175g/kg and RUKANG PIAN 0.28g/kg of Pu Chai has obvious inhibitory action to the swollen granulation tissue hyperplasia of rat cotton balls, and the Pu Chai addiction sheet 0.7g/kg group effect that disappears is the strongest.
Three, xylol causes the impact of mice ear
Get 50 of 20g ± 2g mice, be divided at random 5 groups, be respectively matched group (distilled water), positive control drug RUKANG PIAN group (0.4g/kg) and the Pu bavin addiction sheet group (1,0.5,0.25g/kg) that disappears.The gastric infusion of dosage shown in pressing, every day 1 time, continuous 8 days, matched group gave the equal-volume distilled water.Smeared dimethylbenzene 0.1ml/ only in the Mus auris dextra in 1 hour after the last administration, be coated with rear 4h and put to death mice, along the auricle baseline with directly through being that the sharp card punch of 9mm is laid the ears sheet in same area, weigh respectively, calculate its difference as swelling.The results are shown in Table 5.
The disappear impact of the mice auricle swelling degree that addiction sheet xylol causes of table 5 Pu bavin
Compare * P＜0.05 with matched group
The result shows: disappear addiction sheet 1,0.5g/kg of RUKANG PIAN 0.4g/kg group and Pu bavin organized the mice ear that xylol causes and had obvious inhibitory action, relatively has significant difference with matched group.
Four, Dichlorodiphenyl Acetate causes the impact of mouse writhing reaction
Get 50 of mices, divide equally at random five groups, be respectively matched group (distilled water), positive control drug RUKANG PIAN group (0.4g/kg) and the Pu bavin addiction sheet group (1,0.5,0.25g/kg) that disappears.Hungry 15h before the administration group mice gastric infusion every day one-time continuous administration 8 days, last administration, 1h respectively organizes mouse peritoneal and only injects 0.8% glacial acetic acid 0.2ml/ after the last administration, and mouse writhing number of times in rear 5 minutes～15 minutes injected in record, the results are shown in Table 6.
The table 6. Pu bavin addiction sheet Dichlorodiphenyl Acetate that disappears causes the impact of mice pain reaction
Compare * P＜0.05 with matched group
The result shows, RUKANG PIAN 0.4g/kg and the Pu Chai mouse writhing reaction that addiction sheet 1,0.5g/kg Dichlorodiphenyl Acetate cause that disappears has obvious inhibitory action.
Claims (2)
1. Chinese medicine for the treatment of acute and chronic mammary hyperplasia, it is characterized in that: the Chinese crude drug by following parts by weight is made, 4～20 parts of Herba Taraxacis, 2～10 parts of Radix Bupleuri, 2～10 parts of parch skins, 2～10 parts of Bulbus Fritillariae Thunbergiis, 2～10 parts of Radix Curcumaes, 3～15 parts of Fructus Trichosanthis, 2～10 parts of Radix Angelicae Sinensis, 2～10 parts of stir-fry Rhizoma Cyperis;
Preparation method is:
A, with aforementioned various medical materials clean dry after, with Pericarpium Citri Reticulatae Viride, Rhizoma Cyperi parch, get half pulverizing of Pericarpium Citri Reticulatae Viride, cross 100 mesh sieves for subsequent use;
B, Radix Bupleuri, Bulbus Fritillariae Thunbergii, Radix Angelicae Sinensis added the alcohol reflux twice of 6-10 times of weight, concentration 40-90%, then filter, the extractum of relative density 1.10-1.40 with filtrate recycling ethanol and when being concentrated into 60 degrees centigrade;
C, half Pericarpium Citri Reticulatae Viride, Herba Taraxaci, Fructus Trichosanthis, Radix Curcumae, the Rhizoma Cyperi that pulverizing is remaining decoct with water three times, the 6-12 that each amount of water is raw material weight doubly, then each the decoction 1-4 hour filter the extractum of relative density 1.10-1.40 when filtrate is concentrated into 60 degrees centigrade;
D, with two kinds of extractum of gained and Pericarpium Citri Reticulatae Viride fine powder mixing among step b and the step c, in 50-80 degree centigrade of drying under reduced pressure, add the appropriate amount of auxiliary materials mixed pelletization after pulverizing, add proper amount of dry starch and lubricant, mixing must be treated the Chinese medicine of acute and chronic mammary hyperplasia.
2. a kind of Chinese medicine for the treatment of acute and chronic mammary hyperplasia according to claim 1, it is characterized in that: used Chinese crude drug parts by weight are 12 parts of Herba Taraxacis, 6 parts of Radix Bupleuri, 6 parts of parch skins, 6 parts of Bulbus Fritillariae Thunbergiis, 6 parts of Radix Curcumaes, 9 parts of Fructus Trichosanthis, 6 parts of Radix Angelicae Sinensis, 6 parts of stir-fry Rhizoma Cyperis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810051138 CN101664533B (en) | 2008-09-04 | 2008-09-04 | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810051138 CN101664533B (en) | 2008-09-04 | 2008-09-04 | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101664533A CN101664533A (en) | 2010-03-10 |
| CN101664533B true CN101664533B (en) | 2013-04-03 |
Family
ID=41801415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810051138 Active CN101664533B (en) | 2008-09-04 | 2008-09-04 | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101664533B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908603B (en) * | 2012-10-30 | 2014-06-18 | 王凤 | Chinese medicament for treating hyperplasia of mammary glands |
| CN107007772A (en) * | 2017-05-15 | 2017-08-04 | 铜仁市凯盛水产养殖有限公司 | A kind of cold water fish forage Chinese medicine additive and preparation method thereof |
| CN107569651A (en) * | 2017-09-13 | 2018-01-12 | 李晓艳 | A kind of emplastrum for treating proliferation of mammary gland mastitis |
| CN115887565A (en) * | 2023-01-06 | 2023-04-04 | 河南比福制药股份有限公司 | Radix linderae decoction for liver depression and qi stagnation and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857670A (en) * | 2006-03-21 | 2006-11-08 | 吉林省中医中药研究院 | Medicine for treating hyperplasia of mammary glands and its preparing method |
-
2008
- 2008-09-04 CN CN 200810051138 patent/CN101664533B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857670A (en) * | 2006-03-21 | 2006-11-08 | 吉林省中医中药研究院 | Medicine for treating hyperplasia of mammary glands and its preparing method |
Non-Patent Citations (2)
| Title |
|---|
| 张凤仙等.中西医结合治疗乳腺增生病的研究进展.《云南中医中药杂志》.2007,第28卷(第1期),第43-45页. * |
| 秦元刚等.乳腺增生病的中医药治疗研究.《中原医刊》.2005,第32卷(第24期),第43、44页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101664533A (en) | 2010-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009062338A1 (en) | A lactogenic chinese medicine for treatment and prevention of gynecopathy, methods of preparation and uses thereof | |
| CN104162094B (en) | A kind of Chinese medicine composition and its pharmaceutical preparation for treating Obesity-type Polycystic Ovary Syndrome | |
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN101664533B (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN101007151A (en) | Traditional Chinese medicine and its preparation for treating chronic nephritis | |
| CN101129971B (en) | Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same | |
| CN102526342B (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN101664541B (en) | Medicament for treating dysmenorrhoea and preparation method thereof | |
| CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN103212054A (en) | Chinese medicine composition for treating infertility of women and preparation method thereof | |
| CN110368445A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN113599475B (en) | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
| CN106390035A (en) | Traditional Chinese medicine preparation for treating mammary gland hyperplasia | |
| CN101564483B (en) | Liver smoothing for treating hyperplasia of mammary glands | |
| CN104547789A (en) | Traditional Chinese medicine for treating qi and blood deficiency type postpartum hypogalactia and preparation method thereof | |
| CN104587316B (en) | Anti-gout composition and its preparation method and application | |
| CN104147268B (en) | Traditional Chinese medicine composition and preparation thereof for treating hepatic and gallbladder calculus | |
| CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
| CN105853796A (en) | Medicine composition for treating habitual abortion | |
| CN106540168B (en) | Traditional Chinese medicine composition for treating kidney deficiency type irregular menstruation, amenorrhea and infertility as well as preparation method and application thereof | |
| CN104645245B (en) | A kind of preparation method for Menopause depression pharmaceutical preparation | |
| CN101670067A (en) | Medicament for treating endometriosis and preparation process thereof | |
| CN102038771B (en) | Application of discolor cinquefoil herb in preparation of medicines for treating hysteromyoma | |
| CN112494560A (en) | Preparation process of Chinese patent medicine for treating prostate disease | |
| CN102309683B (en) | Application of traditional Chinese medicinal composition in preparing medicines for treating hysteromyoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN MODERN CHINESE MEDICINE ENGINEERING RESEARCH Free format text: FORMER OWNER: LI YANHUA Effective date: 20131010 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20131010 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee after: Jilin Modern Chinese Medicine Engineering Research Center Co., Ltd. Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Li Yanhua |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181119 Address after: No. 39, Modified Road, Tonghua City, Jilin Province, 134000 Patentee after: Tongyao Pharmaceutical Group Corporation Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin, China Patentee before: Jilin Modern Chinese Medicine Engineering Research Center Co., Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A traditional Chinese medicine for treating acute and chronic hyperplasia of mammary glands and its preparation method Effective date of registration: 20201126 Granted publication date: 20130403 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: Tongyao Pharmaceutical Group Corp. Registration number: Y2020220000086 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211221 Granted publication date: 20130403 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: Tongyao Pharmaceutical Group Corp. Registration number: Y2020220000086 |